Author

Pratishtha Singh

The University of Texas MD Anderson Cancer CenterORCID 0000-0002-9197-7241Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Abhinav K. JainiD· 1 shared Aminah J. Tannir· 1 shared Anurag Majumdar· 1 shared Bidisha ChakrabortyiD· 1 shared Byron Hing Lung LeeiD· 1 shared Deblina Raychaudhuri· 1 shared Jessalyn Hawkins· 1 shared Kadir Caner AkdemiriD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Abhinav K. JainORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer.

Pratishtha Singh, Ranit D’Rozario, Bidisha Chakraborty, Swadhin Meher, Deblina Raychaudhuri, Aminah J. Tannir, Yang Li, Anurag Majumdar, Jessalyn Hawkins, Yun zhao Xiong, Philip L. Lorenzi, Padmanee Sharma, Kadir Caner Akdemir, Patrick Glen Pilie, Abhinav K. Jain, , Sangeeta Goswami

This study shows KDM6A mutations in bladder cancer improve response to immune checkpoint therapy but worsen chemotherapy outcomes through effects on DNA repair and metabolic reprogramming.

Nature Communications · Jan 7, 2026Peer-reviewedImmunology